Post-remission intervention with alemtuzumab or rituximab to eradicate minimal residual disease in chronic lymphocytic leukemia: where do we stand?

References

• Hallek M, Fischer K, Fingerle-Rowson G, . Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010;376:1164–1174.
   PubMed Web of Science ®Google Scholar
• Keating MJ, O'Brien S, Albitar M, . Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005;23:4079–4088.
   PubMed Web of Science ®Google Scholar
• Sayala HA, Rawstron AC, Hillmen P. Minimal residual disease assessment in chronic lymphocytic leukaemia. Best Pract Res Clin Haematol 2007;20:499–512.
   PubMed Web of Science ®Google Scholar
• Wierda W, O'Brien S, Wen S, . Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 2005;23:4070–4078.
   PubMed Web of Science ®Google Scholar
• Bosch F, Abrisqueta P, Villamor N, . Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia. J Clin Oncol 2009;27:4578–4584.
   PubMed Web of Science ®Google Scholar
• Kay NE, Geyer SM, Call TG, . Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood 2007;109:405–411.
   PubMed Web of Science ®Google Scholar
• Bosch F, Ferrer A, Villamor N, . Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication. Clin Cancer Res 2008;14: 155–161.
   PubMed Web of Science ®Google Scholar
• Moreno C, Villamor N, Colomer D, . Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia. Blood 2006;107:4563–4569.
   PubMed Web of Science ®Google Scholar
• Lin TS, Donohue KA, Byrd JC, . Consolidation therapy with subcutaneous (SC) alemtuzumab after fludarabine and rituximab (FR) induction therapy improves the complete response (CR) rate in chronic lymphocytic leukemia (CLL) and eradicates minimal residual disease (MRD) but is associated with severe infectious toxicity: final analysis of CALGB study 10101. Blood 2009;114(Suppl. 1): Abstract 210.
   Google Scholar
• Boettcher S, Fischer K, Stilgenbauer S, ., and on behalf of GCLLSG5. Quantitative MRD assessments predict progression free survival in CLL patients treated with fludarabine and cyclophosphamide with or without rituximab – a prospective analysis in 471 patients from the randomized GCLLSG CLL8 trial. Blood 2008;112(Suppl. 1): Abstract 326.
   Google Scholar
• Tam CS, O'Brien S, Wierda W, . Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008;112:975–980.
   PubMed Web of Science ®Google Scholar
• Ysebaert L, Gross E, Kuhlein E, . Immune recovery after fludarabine-cyclophosphamide-rituximab treatment in B-chronic lymphocytic leukemia: implication for maintenance immunotherapy. Leukemia 2010;24:1310–1316.
   PubMed Web of Science ®Google Scholar
• Lamanna N, Jurcic JG, Noy A, . Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses. J Clin Oncol 2009;27:491–497.
   PubMed Web of Science ®Google Scholar
• Lundin J, Kimby E, Bjorkholm M, . Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002;100:768–773.
   PubMed Web of Science ®Google Scholar
• Hillmen P, Skotnicki AB, Robak T, . Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007;25:5616–5623.
   PubMed Web of Science ®Google Scholar
• Kwok M, Rawstron AC, Varghese A, . Minimal residual disease is a predictor for progression-free and overall survival in chronic lymphocytic leukemia (CLL) that is independent of the type or line of therapy. Blood 2009;114(Suppl. 1): Abstract 540.
   PubMed Web of Science ®Google Scholar
• Moreton P, Kennedy B, Lucas G, . Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 2005;23:2971–2979.
   PubMed Web of Science ®Google Scholar
• Hallek M, Cheson BD, Catovsky D, . Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008;111:5446–5456.
   PubMed Web of Science ®Google Scholar
• Rawstron AC, Villamor N, Ritgen M, . International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia 2007;21:956–964.
   PubMed Web of Science ®Google Scholar
• Bottcher S, Stilgenbauer S, Busch R, . Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysis. Leukemia 2009;23:2007–2017.
   PubMed Web of Science ®Google Scholar
• Letestu R, Leprêtre S, Arnoulet C, . CLL2007FMP, a phase III randomized multicentric trial of the French cooperative group on CLL and WM (FCGCLL/MW) and the “Groupe Ouest-Est d'Etudes des Leucémies Aigües et Autres Maladies du Sang” (GOELAMS): immunochemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) yields a significantly better response than fludarabine (F), cyclophosphamide © and MabCampath (Cam) (FCCam) in previously untreated B-chronic lymphocytic leukemia patients as evaluated by a sensitive 6 color flow cytometry MRD. Blood 2010;116(Suppl. 1): Abstract 698.
   PubMed Web of Science ®Google Scholar
• Hallek M. State-of-the-art treatment of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2009:440–449.
   PubMedGoogle Scholar
• Lepretre S, Aurran T, Mahe B, . Immunochemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus fludarabine (F), cyclophosphamide (C) and MabCampath (Cam) (FCCam) in previously untreated patients (pts) with advanced B-chronic lymphocytic leukemia (B-CLL): experience on safety and efficacy within a randomised multicenter phase III trial of the French cooperative group on CLL and WM (FCGCLL/MW) and the “Groupe Ouest-Est d'Etudes des Leucémies Aigües et Autres Maladies du Sang” (GOELAMS): CLL2007FMP (for fit medically patients). Blood 2009;114(Suppl. 1): Abstract 538.
   Google Scholar
• Wierda WG, O'Brien S, Ferrajoli A, . Combined cyclophosphamide, fludarabine, alemtuzumab, and rituximab (CFAR), an active frontline regimen for high-risk patients with CLL. Blood 2007;110(Suppl. 1): Abstract 628.
   Google Scholar
• Tsimberidou AM, Tam C, Abruzzo LV, . Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia. Cancer 2009;115:373–380.
   PubMed Web of Science ®Google Scholar
• Faderl S, Wierda W, O'Brien S, . Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL < 70 years. Leuk Res 2010;34:284–288.
   PubMed Web of Science ®Google Scholar
• Alatrash G, Albitar M, O'Brien S, . Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR). Br J Haematol 2010;148: 386–393.
   PubMed Web of Science ®Google Scholar
• Robak T, Blonski JZ, Gora-Tybor J, . Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2). Blood 2006;108:473–479.
   PubMed Web of Science ®Google Scholar
• Fischer K, Cramer P, Stilgenbauer S, ., and the German CLL Study Group (GCLLSG). Bendamustine combined with rituximab (BR) in first-line therapy of advanced CLL: a multicenter phase II trial of the German CLL Study Group (GCLLSG). Blood 2009;114(Suppl. 1): Abstract 205.
   Google Scholar
• Montillo M, Tedeschi A, Miqueleiz S, . Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia. J Clin Oncol 2006;24:2337–2342.
   PubMed Web of Science ®Google Scholar
• Lin TS, Donohue KA, Byrd JC, . Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101. J Clin Oncol 2010;28:4500–4506.
   PubMed Web of Science ®Google Scholar
• Wierda WG, Kipps TJ, Keating MJ, . Self-administered, subcutaneous alemtuzumab to treat residual disease in patients with chronic lymphocytic leukemia. Cancer 2011;117:116–124.
   PubMed Web of Science ®Google Scholar
• O'Brien SM, Kantarjian HM, Thomas DA, . Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer 2003;98:2657–2663.
   PubMed Web of Science ®Google Scholar
• Schweighofer CD, Ritgen M, Eichhorst BF, . Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG). Br J Haematol 2009;144:95–98.
   PubMed Web of Science ®Google Scholar
• Wendtner CM, Ritgen M, Schweighofer CD, . Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission—experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia 2004;18:1093–1101.
   PubMed Web of Science ®Google Scholar
• Dyer MJ, Kelsey SM, Mackay HJ, . In vivo “purging” of residual disease in CLL with Campath-1H. Br J Haematol 1997;97:669–672.
   PubMed Web of Science ®Google Scholar
• Delmer A, Lepretre S, Cazin B, . Consolidation therapy with subcutaneous alemtuzumab following induction treatment with oral FC (fludarabine and cyclophosphamide) in previously untreated patients aged 65-70 years with advanced stage chronic lymphocytic leukemia (CLL): a phase II trial of the FCGCLL/MW. Blood 2006;108(Suppl. 1): Abstract 2831.
   PubMed Web of Science ®Google Scholar
• Hainsworth JD, Vazquez ER, Spigel DR, . Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase 2 trial of the Minnie Pearl Cancer Research Network. Cancer 2008;112:1288–1295.
   PubMed Web of Science ®Google Scholar
• Kaufman MS, Caramanica A, Janson D, . Alemtuzumab maintenance may safely prolong chemotherapy-free intervals in chronic lymphocytic leukemia. Med Oncol 2100;28:532–538.
   Google Scholar
• Thieblemont C, Bouafia F, Hornez E, . Maintenance therapy with a monthly injection of alemtuzumab prolongs response duration in patients with refractory B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (B-CLL/SLL). Leuk Lymphoma 2004;45:711–714.
   PubMed Web of Science ®Google Scholar
• Stilgenbauer S, Cymbalista F, Leblond V, . Subcutaneous alemtuzumab combined with oral dexamethasone, followed by alemtuzumab maintenance or allo-SCT in CLL with 17p- or refractory to fludarabine – interim analysis of the CLL2O trial of the GCLLSG and FCGCLL/MW. Blood 2010;116(Suppl. 1): Abstract 920.
   Google Scholar
• O'Brien SM, Kantarjian H, Thomas DA, . Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001;19:2165–2170.
   PubMed Web of Science ®Google Scholar
• Del Poeta G, Del Principe MI, Buccisano F, . Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia. Cancer 2008;112:119–128.
   PubMed Web of Science ®Google Scholar
• Garcia-Marco JA, Lopez-Jimenez J, Ferrer S, . Rituximab maintenance treatment after combined fludarabine, cyclophosphamide and rituximab in previously untreated patients with progressive B-cell chronic lymphocytic leukemia (CLL): interim analysis of an ongoing phase II multicenter trial on behalf of the Spanish CLL Study Group (GELLC). Blood 2010;116(Suppl. 1): Abstract 2448.
   Google Scholar
• Egle A, Weiss L, Melchardt T, . Final analysis of induction treatment with fludarabine, cyclophosphamide plus rituximab (FCR) followed by fludarabine plus rituximab (FR) and remission maintenance therapy with rituximab in previously untreated B-chronic lymphocytic leukemia (B-CLL): the Chairos AGMT CLL4/Roche ML18434 study. Blood 2010;116(Suppl. 1): Abstract 1380.
   Google Scholar
• Byrd JC, Peterson BL, Morrison VA, . Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 2003;101:6–14.
   PubMed Web of Science ®Google Scholar
• Scaramucci L, Niscola P, Buffolino S, . Repeated rituximab maintenance courses in fludarabine-failed young patients with chronic lymphocytic leukaemia responding to FAND chemotherapy. Hematol J 2004;5:186–187.
   PubMedGoogle Scholar
• Foon KA, Boyiadzis M, Land SR, . Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009;27:498–503.
   PubMed Web of Science ®Google Scholar
• Hainsworth JD, Litchy S, Barton JH, . Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2003;21:1746–1751.
   PubMed Web of Science ®Google Scholar
• Srock S, Schriever F, Neubauer A, . Long-term treatment with rituximab is feasible in selected patients with B-CLL: response-adjusted low-dose maintenance treatment with rituximab in patients with relapsed B-CLL, who achieved a partial or minimal response to prior rituximab therapy. Leuk Lymphoma 2007;48:905–911.
   PubMed Web of Science ®Google Scholar
• Hainsworth JD. First-line and maintenance treatment with rituximab for patients with indolent non-Hodgkin's lymphoma. Semin Oncol 2003;30:9–15.
   PubMed Web of Science ®Google Scholar
• Foa R, Ciolli S, Di Raimondo F, . A phase II study of chlorambucil plus rituximab followed by maintenance versus observation in elderly patients with previously untreated chronic lymphocytic leukemia: results of the first interim analysis. Blood 2010;116(Suppl. 1): Abstract 2462.
   Google Scholar
• Ferrajoli A. Treatment of younger patients with chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2010:82–89.
   PubMedGoogle Scholar
• Moccia A, Ghielmini M. Monoclonal antibodies for the treatment of hematologic malignancies: schedule and maintenance therapy. Semin Hematol 2008;45:75–84.
   PubMed Web of Science ®Google Scholar
• Fischer K, Schweighofer C, Ritgen M, . Dose escalation study to evaluate dose limiting toxicity (DLT), maximum tolerated dose (MTD) and safety of alemtuzumab for consolidation therapy in patients with chronic lymphoycytic leukemia: phase I/II trial of the German CLL Study Group (GCLLSG). Blood 2007;110(Suppl. 1): Abstract 2053.
   Google Scholar
• Maung ZT, Wood AC, Jackson GH, . Transfusion-associated graft-versus-host disease in fludarabine-treated B-chronic lymphocytic leukaemia. Br J Haematol 1994;88:649–652.
   PubMed Web of Science ®Google Scholar
• Kluin-Nelemans HC, Coenen JL, Boers JE, . EBV-positive immunodeficiency lymphoma after alemtuzumab-CHOP therapy for peripheral T-cell lymphoma. Blood 2008;112:1039–1041.
   PubMed Web of Science ®Google Scholar
• Wolach O, Bairey O, Lahav M. Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature. Medicine (Baltimore) 2010;89:308–318.
   PubMed Web of Science ®Google Scholar
• Vidal L, Gafter-Gvili A, Leibovici L, . Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials. J Natl Cancer Inst 2009;101:248–255.
   PubMed Web of Science ®Google Scholar
• van Oers MH, Van Glabbeke M, Giurgea L, . Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol 2010;28:2853–2858.
   PubMed Web of Science ®Google Scholar
• Salles G, Seymour JF, Offner F, . Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 2011;377:42–51.
   PubMed Web of Science ®Google Scholar
• Casulo C, Maragulia J, Zelenetz A. Hypogammaglobulinemia in pts receiving rituximab immunotherapy and the impact of rituximab maintenance. J Clin Oncol 2010;28(15 Suppl.): Abstract 8088.
   Web of Science ®Google Scholar
• Gea-Banacloche JC. Rituximab-associated infections. Semin Hematol 2010;47:187–198.
   PubMed Web of Science ®Google Scholar
• D'Souza A, Wilson J, Mukherjee S, . Progressive multifocal leukoencephalopathy in chronic lymphocytic leukemia: a report of three cases and review of the literature. Clin Lymphoma Myeloma Leuk 2010;10:E1–E9.
   PubMed Web of Science ®Google Scholar
• Yagci M, Ozkurt ZN, Yegin ZA, . Hepatitus B virus reactivation in HBV-DNA negative and positive patients with hematological malignancies. Hematology 2010;15:240–244.
   PubMed Web of Science ®Google Scholar
• Bitzan M, Anselmo M, Carpineta L. Rituximab (B-cell depleting antibody) associated lung injury (RALI): a pediatric case and systematic review of the literature. Pediatr Pulmonol 2009;44:922–934.
   PubMed Web of Science ®Google Scholar
• Dayde D, Ternant D, Ohresser M, . Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20. Blood 2009;113:3765–3772.
   PubMed Web of Science ®Google Scholar
• Li J, Zhi J, Wenger M, . Higher doses of rituximab may be required for patients with CLL as compared to NHL based on population pharmacokinetic (PK) modeling. Blood 2009;114(Suppl. 1): Abstract 1742.
   Google Scholar
• Manshouri T, Do KA, Wang X, . Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood 2003;101:2507–2513.
   PubMed Web of Science ®Google Scholar
• Beum PV, Kennedy AD, Taylor RP. Three new assays for rituximab based on its immunological activity or antigenic properties: analyses of sera and plasmas of RTX-treated patients with chronic lymphocytic leukemia and other B cell lymphomas. J Immunol Methods 2004;289:97–109.
   PubMed Web of Science ®Google Scholar
• Beers SA, French RR, Chan HT, . Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood 2010;115:5191–5201.
   PubMed Web of Science ®Google Scholar
• Taylor RP, Lindorfer MA. Antigenic modulation and rituximab resistance. Semin Hematol 2010;47:124–132.
   PubMed Web of Science ®Google Scholar
• Ritz J, Schlossman SF. Utilization of monoclonal antibodies in the treatment of leukemia and lymphoma. Blood 1982;59:1–11.
   PubMed Web of Science ®Google Scholar
• Beum PV, Kennedy AD, Williams ME, . The shaving reaction: rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes. J Immunol 2006;176:2600–2609.
   PubMed Web of Science ®Google Scholar
• Taylor R, Beum P, Lindorfer M, . Examination of the relative rates of rituximab-mediated loss of CD20 from B cells via trogocytosis versus internalization. Implications for rituximab therapy of CLL. Blood 2010;116(Suppl. 1): Abstract 2404.
   Google Scholar
• Kennedy AD, Beum PV, Solga MD, . Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J Immunol 2004;172:3280–3288.
   PubMed Web of Science ®Google Scholar
• D'Auria F, Guariglia R, Villani O, . Modulation of CD20 antigen expression after rituximab treatment: a retrospective study in patients with chronic lymphocytic leukemia. Clin Ther 2010;32:1911–1916.
   PubMed Web of Science ®Google Scholar
• Williams ME, Densmore JJ, Pawluczkowycz AW, . Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia. J Immunol 2006;177:7435–7443.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Murphy T, Howard RS, . Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 2001;19:2153–2164.
   PubMed Web of Science ®Google Scholar
• Aue G, Lindorfer MA, Beum PV, . Fractionated subcutaneous rituximab is well-tolerated and preserves CD20 expression on tumor cells in patients with chronic lymphocytic leukemia. Haematologica 2010;95:329–332.
   PubMed Web of Science ®Google Scholar
• Mankai A, Buhe V, Hammadi M, . Improvement of rituximab efficiency in chronic lymphocytic leukemia by CpG-mediated upregulation of CD20 expression independently of PU.1. Ann NY Acad Sci 2009;1173:721–728.
   PubMed Web of Science ®Google Scholar
• Sivaraman S, Deshpande CG, Ranganathan R, . Tumor necrosis factor modulates CD 20 expression on cells from chronic lymphocytic leukemia: a new role for TNF alpha? Microsc Res Tech 2000;50:251–257.
   PubMed Web of Science ®Google Scholar
• Klepfish A, Gilles L, Ioannis K, . Enhancing the action of rituximab in chronic lymphocytic leukemia by adding fresh frozen plasma: complement/rituximab interactions & clinical results in refractory CLL. Ann NY Acad Sci 2009;1173:865–873.
   PubMed Web of Science ®Google Scholar
• Ferrajoli A. Incorporating the use of GM-CSF in the treatment of chronic lymphocytic leukemia. Leuk Lymphoma 2009;50:514–516.
   PubMed Web of Science ®Google Scholar
• Poire X, Kline J, Grinblatt D, . Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas. Leuk Lymphoma 2010;51:1241–1250.
   PubMed Web of Science ®Google Scholar
• Wu L, Adams M, Carter T, . Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20 + tumor cells. Clin Cancer Res 2008;14:4650–4657.
   PubMed Web of Science ®Google Scholar
• Andersen NS, Pedersen LB, Laurell A, . Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma. J Clin Oncol 2009;27:4365–4370.
   PubMed Web of Science ®Google Scholar
• O'Brien S, Kay NE. Maintenance therapy for B-chronic lymphocytic leukemia. Clin Adv Hematol Oncol 2011;9:22–31.
   PubMedGoogle Scholar